Vol 74, Supp. A (2023)
Guidelines / Expert consensus
Published online: 2023-04-28

open access

Page views 1887
Article views/downloads 31
Get Citation

Connect on Social Media

Connect on Social Media

Zalecenia postępowania diagnostycznego i leczniczego w osteoporozie w Polsce. Aktualizacja 2022

Piotr Głuszko1, Ewa Sewerynek, Waldemar Misiorowski, Jerzy Konstantynowicz, Ewa Marcinowska-Suchowierska, Tomasz Blicharski, Mirosław Jabłoński, Edward Franek, Tomasz Kostka, Maciej Jaworski, Elżbieta Karczmarewicz, Ewa Kalinka, Krystyna Księżopolska-Orłowska, Andrzej Więcek, Roman S. Lorenc
DOI: 10.5603/ep.94310

Abstract

Prezentowane zalecenia stanowią aktualizację opublikowanych wcześniej polskich wytycznych (2017) dotyczących postępowania w przypadkach osteoporozy u kobiet i mężczyzn. Opracowano je zgodnie z postępem wiedzy medycznej, na podstawie dowodów naukowych z uwzględnieniem nowych strategii diagnostycznych i terapeutycznych. Grupa Robocza ekspertów z Wielodyscyplinarnego Forum Osteoporozy oraz Narodowego Instytutu Geriatrii, Reumatologii i Rehabilitacji w Warszawie dokonała kompleksowego przeglądu aktualnego piśmiennictwa z tej dziedziny (z ujęciem wszystkich grup wiekowych i zasad leczenia osteoporozy wtórnej), uwzględniła dostępne dane epidemiologiczne dotyczące osteoporozy w Polsce, oceniła koszty oraz obowiązujące standardy opieki.

Wszyscy współautorzy opracowania weryfikowali jakość dowodów naukowych w celu sformułowania 29 konkretnych zaleceń i w niezależnym głosowaniu określili „siłę” każdego zalecenia. W uaktualnionych rekomendacjach zwrócono uwagę na nowy algorytm postępowania diagnostyczno-terapeutycznego u osób z wysokim i bardzo wysokim ryzykiem złamań, przedstawiono zasady ogólnego postępowania terapeutycznego oraz stosowania leków, w tym leków o działaniu anabolicznym. Omówiono strategię pierwotnej i wtórnej profilaktyki złamań, wykrywania złamań niskoenergetycznych w populacji oraz wskazano na istotne elementy dotyczące poprawy leczenia osteoporozy w Polsce.

Article available in PDF format

View PDF Download PDF file

References

  1. Lorenc R, Głuszko P, Franek E, et al. Guidelines for the diagnosis and management of osteoporosis in Poland : Update 2017. Endokrynol Pol. 2017; 68(5): 604–609.
  2. Głuszko P, Lorenc RS, Karczmarewicz E, et al. Working Group including the representatives of the Polish Associations of Orthopedics and Traumatology, Rehabilitation, Gerontology, Rheumatology, Family Medicine, Diabetology, Laboratory Diagnostics, Andropause and Menopause, Endocrinology, Radiology, and the STENKO group. Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 update. Pol Arch Med Wewn. 2014; 124(5): 255–263.
  3. Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020; 31(1): 1–12.
  4. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/ American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 Update. Endocr Pract. 2020; 26(5): 564–570.
  5. Ferrari S, Lippuner K, Lamy O, et al. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly. 2020; 150: w20352.
  6. Eastell R, Vittinghoff E, Lui LY, et al. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. J Bone Miner Res. 2022; 37(1): 29–35.
  7. Kanis JA, Cooper C, Rizzoli R, et al. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019; 30(1): 3–44.
  8. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016; 31(1): 16–35.
  9. Vandenput L, Johansson H, McCloskey EV, et al. Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporos Int. 2022; 33(10): 2103–2136.
  10. Galindo-Zavala R, Bou-Torrent R, Magallares-López B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J. 2020; 18(1): 20.
  11. Herath M, Cohen A, Ebeling PR, et al. Dilemmas in the Management of Osteoporosis in Younger Adults. JBMR Plus. 2022; 6(1): e10594.
  12. Willers C, Norton N, Harvey NC, et al. SCOPE review panel of the IOF. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022; 17(1): 23.
  13. Narodowy Fundusz Zdrowia. NFZ o Zdrowiu: Osteoporoza. Centrala Narodowego Funduszu Zdrowia, Departament Analiz i Strategii, Warszawa 2019.
  14. Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014; 25(5): 1439–1443.
  15. McLellan AR, Gallacher SJ, Fraser M, et al. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int. 2003; 14(12): 1028–1034.
  16. Black DM, Geiger EJ, Eastell R, et al. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020; 383(8): 743–753.
  17. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843: 1–129.
  18. Kanis JA, Johansson H, Harvey NC, et al. Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporos Int. 2020; 31(10): 1817–1828.
  19. Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022; 17(1): 58.
  20. Geusens P, Appelman-Dijkstra NM, Zillikens MC, et al. How to implement guidelines and models of care. Best Pract Res Clin Rheumatol. 2022; 36(3): 101759.
  21. Vilaca T, Eastell R, Schini M. Osteoporosis in men. Lancet Diabetes Endocrinol. 2022; 10(4): 273–283.
  22. Kanis JA, McCloskey EV, Harvey NC, et al. Intervention Thresholds and the Diagnosis of Osteoporosis. J Bone Miner Res. 2015; 30(10): 1747–1753.
  23. Kanis J, Harvey N, Cooper C, et al. A systematic review of intervention thresholds based on FRAX. Arch Osteoporos. 2016; 11(1).
  24. Mitchell P, Åkesson K, Chandran M, et al. Implementation of Models of Care for secondary osteoporotic fracture prevention and orthogeriatric Models of Care for osteoporotic hip fracture. Best Pract Res Clin Rheumatol. 2016; 30(3): 536–558.
  25. Czerwinski E, Czubak J, Mazurek T. Zasady profilaktyki, rozpoznawania i leczenia osteoporotycznych złamań kości. Ortopedia Traumatologia Rehabilitacja. 2022; 4: 281–292.
  26. Or O, Fisher Negev T, Hadad V, et al. Fracture Liaison Service for Hip Fractures: Is It A Game Changer? Isr Med Assoc J. 2021; 23(8): 490–493.
  27. Weil YA, Bernstein BP, Maqungo S, et al. Hip fracture care and national systems in Israel and South Africa. OTA Int. 2020; 3(1): e065.
  28. Kanis JA, Cooper C, Rizzoli R, et al. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int. 2019; 104(3): 235–238.
  29. Cosman F, de Beur SJ, LeBoff MS, et al. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10): 2359–2381.
  30. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004; 164(10): 1108–1112.
  31. Cosman F, de Beur SJ, LeBoff MS, et al. Erratum to: Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2015; 26(7): 2045–2047.
  32. Briot K. DXA parameters: beyond bone mineral density. Joint Bone Spine. 2013; 80(3): 265–269.
  33. Silva BC, Leslie WD. Trabecular Bone Score: A New DXA-Derived Measurement for Fracture Risk Assessment. Endocrinol Metab Clin North Am. 2017; 46(1): 153–180.
  34. Rajan R, Cherian KE, Kapoor N, et al. Trabecular Bone Score-An Emerging Tool in the Management of Osteoporosis. Indian J Endocrinol Metab. 2020; 24(3): 237–243.
  35. Cozadd AJ, Schroder LK, Switzer JA. Fracture Risk Assessment: An Update. J Bone Joint Surg Am. 2021; 103(13): 1238–1246.
  36. Nowakowska-Płaza A, Wroński J, Sudoł-Szopińska I, et al. Clinical Utility of Trabecular Bone Score (TBS) in Fracture Risk Assessment of Patients with Rheumatic Diseases Treated with Glucocorticoids. Horm Metab Res. 2021; 53(8): 499–503.
  37. McCloskey EV, Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res. 2016; 31(5): 940–948.
  38. McCloskey EV, Odén A, Harvey NC, et al. Adjusting fracture probability by trabecular bone score. Calcif Tissue Int. 2015; 96(6): 500–509.
  39. Martineau P, Leslie WD. The utility and limitations of using trabecular bone score with FRAX. Curr Opin Rheumatol. 2018; 30(4): 412–419.
  40. Amarowicz J, Krawczyk A, Kumorek A. Utility of fragility fracture prediction tools in a group of postmenopausal women. Reumatologia. 2021; 59(4): 230–236.
  41. Cohen A, Dempster DW, Stein EM, et al. Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab. 2011; 96(10): 3095–3105.
  42. Liu XS, Cohen A, Shane E, et al. Individual trabeculae segmentation (ITS)-based morphological analysis of high-resolution peripheral quantitative computed tomography images detects abnormal trabecular plate and rod microarchitecture in premenopausal women with idiopathic osteoporosis. J Bone Miner Res. 2010; 25(7): 1496–1505.
  43. Ciria-Recasens M, Pérez-Edo L, Blanch-Rubió J, et al. Bone histomorphometry in 22 male patients with normocalciuric idiopathic osteoporosis. Bone. 2005; 36(5): 926–930.
  44. Lapauw B, Vandewalle S, Taes Y, et al. Serum sclerostin levels in men with idiopathic osteoporosis. Eur J Endocrinol. 2013; 168(4): 615–620.
  45. Paccou J, Dewailly J, Cortet B. Reduced levels of serum IGF-1 is related to the presence of osteoporotic fractures in male idiopathic osteoporosis. Joint Bone Spine. 2012; 79(1): 78–82.
  46. Van Pottelbergh I, Goemaere S, Zmierczak H, et al. Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men: evidence from a three-generation family study. J Bone Miner Res. 2003; 18(2): 303–311.
  47. Collet C, Ostertag A, Ricquebourg M, et al. Primary Osteoporosis in Young Adults: Genetic Basis and Identification of Novel Variants in Causal Genes. JBMR Plus. 2018; 2(1): 12–21.
  48. Stürznickel J, Rolvien T, Delsmann A, et al. Clinical Phenotype and Relevance of LRP5 and LRP6 Variants in Patients With Early-Onset Osteoporosis (EOOP). J Bone Miner Res. 2021; 36(2): 271–282.
  49. Cohen A, Hostyk J, Baugh EH, et al. Whole exome sequencing reveals potentially pathogenic variants in a small subset of premenopausal women with idiopathic osteoporosis. Bone. 2022; 154: 116253.
  50. Shuhart CR, Yeap SS, Anderson PA, et al. Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom. 2019; 22(4): 453–471.
  51. Ferrari S, Bianchi ML, Eisman JA, et al. IOF Committee of Scientific Advisors Working Group on Osteoporosis Pathophysiology. Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int. 2012; 23(12): 2735–2748.
  52. Mendoza-Pinto C, Rojas-Villarraga A, Molano-González N, et al. Bone mineral density and vertebral fractures in patients with systemic lupus erythematosus: A systematic review and meta-regression. PLoS One. 2018; 13(6): e0196113.
  53. Sokal A, Elefant E, Leturcq T, et al. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int. 2019; 30(1): 221–229.
  54. Weber TJ, Drezner MK. Effect of alendronate on bone mineral density in male idiopathic osteoporosis. Metabolism. 2001; 50(8): 912–915.
  55. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000; 85(9): 3069–3076.
  56. Cohen A, Shiau S, Nair N, et al. Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial. J Clin Endocrinol Metab. 2020; 105(10): e3540–e3556.
  57. Ward LM, Konji VN, Ma J. The management of osteoporosis in children. Osteoporos Int. 2016; 27(7): 2147–2179.
  58. Bishop N, Arundel P, Clark E, et al. International Society of Clinical Densitometry. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom. 2014; 17(2): 275–280.
  59. Ward LM, Weber DR, Munns CF, et al. A Contemporary View of the Definition and Diagnosis of Osteoporosis in Children and Adolescents. J Clin Endocrinol Metab. 2020; 105(5): e2088–e2097.
  60. Ward LM. Part I: Which Child with a Chronic Disease Needs Bone Health Monitoring? Curr Osteoporos Rep. 2021; 19(3): 278–288.
  61. Bianchi ML, Leonard MB, Bechtold S, et al. International Society for Clinical Densitometry. Bone health in children and adolescents with chronic diseases that may affect the skeleton: the 2013 ISCD Pediatric Official Positions. J Clin Densitom. 2014; 17(2): 281–294.
  62. Roth J, Bechtold S, Borte G, et al. [Diagnosis, prophylaxis and therapy of osteoporosis in juvenile idiopathic arthritis: consensus statement of the German Association for Pediatric Rheumatology]. Z Rheumatol. 2007; 66(5): 434–440.
  63. Clark EM, Tobias JH, Ness AR. Association between bone density and fractures in children: a systematic review and meta-analysis. Pediatrics. 2006; 117(2): e291–e297.
  64. Bianchi ML, Baim S, Bishop NJ, et al. Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol. 2010; 25(1): 37–47.
  65. Rizzoli R, Bianchi ML, Garabédian M, et al. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone. 2010; 46(2): 294–305.
  66. Rusińska A, Płudowski P, Walczak M, et al. Vitamin D Supplementation Guidelines for General Population and Groups at Risk of Vitamin D Deficiency in Poland-Recommendations of the Polish Society of Pediatric Endocrinology and Diabetes and the Expert Panel With Participation of National Specialist Consultants and Representatives of Scientific Societies-2018 Update. Front Endocrinol (Lausanne). 2018; 9: 246.
  67. Brown JJ, Zacharin MR. Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health. 2005; 41(11): 580–582.
  68. Ward LM. Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis? Curr Osteoporos Rep. 2021; 19(3): 289–297.
  69. Ward LM. Glucocorticoid-Induced Osteoporosis: Why Kids Are Different. Front Endocrinol (Lausanne). 2020; 11: 576.
  70. Simm PJ, Biggin A, Zacharin MR, et al. APEG Bone Mineral Working Group. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018; 54(3): 223–233.
  71. Bachrach LK, Ward LM, Gordon CM, et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom. 2008; 11(1): 43–58.
  72. Cavalier E, Eastell R, Rye Jørgensen N, et al. IFCC-IOF Joint Committee for Bone Metabolism (C-BM). A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism. Clin Chem Lab Med. 2019; 57(10): 1546–1555.
  73. Vasikaran SD, Bhattoa HP, Eastell R, et al. Harmonization of commercial assays for PINP; the way forward. Osteoporos Int. 2020; 31(3): 409–412.
  74. Schousboe JT, Bauer DC, Nyman JA, et al. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int. 2007; 18(2): 201–210.
  75. Borgen TT, Solberg LB, Lauritzen T, et al. Target Values and Daytime Variation of Bone Turnover Markers in Monitoring Osteoporosis Treatment After Fractures. JBMR Plus. 2022; 6(6): e10633.
  76. Lane NE, Saag K, O'Neill TJ, et al. Real-world bone turnover marker use: impact on treatment decisions and fracture. Osteoporos Int. 2021; 32(5): 831–840.
  77. Roberts J, Castro C, Moore AEB, et al. Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting. Clin Endocrinol (Oxf). 2016; 84(4): 509–515.
  78. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(1): 16–31.
  79. Fried LP, Tangen CM, Walston J, et al. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56(3): M146–M156.
  80. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001; 49(12): 1691–1699.
  81. Rinonapoli G, Ruggiero C, Meccariello L, et al. Osteoporosis in Men: A Review of an Underestimated Bone Condition. Int J Mol Sci. 2021; 22(4).
  82. Vescini F, Chiodini I, Falchetti A, et al. Management of Osteoporosis in Men: A Narrative Review. Int J Mol Sci. 2021; 22(24).
  83. Borgström F, Karlsson L, Ortsäter G, et al. International Osteoporosis Foundation. Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos. 2020; 15(1): 59.
  84. Katsoulis M, Benetou V, Karapetyan T, et al. Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J Intern Med. 2017; 281(3): 300–310.
  85. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018; 103(5): 1715–1744.
  86. Watts NB, Adler RA, Bilezikian JP, et al. Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97(6): 1802–1822.
  87. Diem SJ, Peters KW, Gourlay ML, et al. Osteoporotic Fractures in Men Research Group. Screening for Osteoporosis in Older Men: Operating Characteristics of Proposed Strategies for Selecting Men for BMD Testing. J Gen Intern Med. 2017; 32(11): 1235–1241.
  88. Su Y, Leung J, Kwok T. The role of previous falls in major osteoporotic fracture prediction in conjunction with FRAX in older Chinese men and women: the Mr. OS and Ms. OS cohort study in Hong Kong. Osteoporos Int. 2018; 29(6): 1469.
  89. Brown JE, Handforth C, Compston JE, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol. 2020; 25: 100311.
  90. Lewiecki EM, Blicharski T, Goemaere S, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018; 103(9): 3183–3193.
  91. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med. 2000; 160(4): 517–525.
  92. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18): 1799–1809.
  93. Carmel AS, Shieh A, Bang H, et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int. 2012; 23(10): 2479–2487.
  94. Eckardt KU, Kasiske BL. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; 76113(113): S1–S130.
  95. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003; 349(17): 1676–9; discussion 1676.
  96. Ding Y, Zeng JC, Yin F, et al. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis. Orthop Surg. 2017; 9(3): 284–289.
  97. Okimoto N, Sakai A, Yoshioka T, et al. Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study. J Bone Miner Metab. 2020; 38(2): 230–239.
  98. Fink HA, MacDonald R, Forte ML, et al. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Ann Intern Med. 2019; 171(1): 37–50.
  99. Lloyd AA, Gludovatz B, Riedel C, et al. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci U S A. 2017; 114(33): 8722–8727.
  100. Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022; 17(1): 58.
  101. Nakamura Y, Suzuki T, Yoshida T, et al. Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis. Nutrients. 2017; 9(5).
  102. Naylor KE, Bradburn M, Paggiosi MA, et al. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int. 2018; 29(6): 1407–1417.
  103. Hayes KN, Winter EM, Cadarette SM, et al. Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making. J Clin Med. 2021; 10(5).
  104. Wang M, Wu YF, Girgis CM. Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real-World Studies. JBMR Plus. 2022; 6(6): e10629.
  105. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5(7): 513–523.
  106. Ferrari S, Lewiecki EM, Butler PW, et al. Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. Bone. 2020; 134: 115287.
  107. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43(2): 222–229.
  108. Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020 [Epub ahead of print].
  109. Cummings SR, Ferrari S, Eastell R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2018; 33(2): 190–198.
  110. Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. J Bone Miner Res. 2017; 32(6): 1291–1296.
  111. Lamy O, Gonzalez-Rodriguez E, Aubry-Rozier B. Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation. J Clin Endocrinol Metab. 2017; 102(6): 2112.
  112. Chapurlat R. Effects and management of denosumab discontinuation. Joint Bone Spine. 2018; 85(5): 515–517.
  113. Tymlos (abaloparatide) injection, for subcutaneous use. Radius Health, Inc., Waltham, MA, 2017. www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf.
  114. Forteo (teriparatide [rDNA origin] injection) for subcutaneous use [package insert]. Eli Lilly and Co, Indianapolis, IN, 2012. https://pi.lilly.com/us/forteo-pi.pdf.
  115. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004; 164(18): 2024–2030.
  116. Shakeri A, Adanty C. Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: A review. J Popul Ther Clin Pharmacol. 2020; 27(1): e25–e31.
  117. Brown JP, Engelke K, Keaveny TM, et al. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. J Bone Miner Res. 2021; 36(11): 2139–2152.
  118. Keaveny TM, Crittenden DB, Bolognese MA, et al. Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass. J Bone Miner Res. 2017; 32(9): 1956–1962.
  119. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016; 375(16): 1532–1543.
  120. Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2019; 34(3): 419–428.
  121. Saag KG, Petersen J, Grauer A, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017; 377(15): 1417–1427.
  122. Singh S, Dutta S, Khasbage S, et al. A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis. Osteoporos Int. 2022; 33(1): 1–12.
  123. Tominaga A, Wada K, Okazaki K, et al. Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment. Osteoporos Int. 2022; 33(6): 1265–1273.
  124. Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017; 390(10102): 1585–1594.
  125. Cosman F, Kendler DL, Langdahl BL, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int. 2022; 33(6): 1243–1256.
  126. Cauley JA, Robbins J, Chen Z, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003; 290(13): 1729–1738.
  127. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res. 2006; 21(6): 817–828.
  128. Evista (raloxifene hydrochloride) tablet for oral use (package insert). Eli Lilly and Co, 2011. https://pi.lilly.com/us/evista-pi.pdf.
  129. Barrett-Connor E, Mosca L, Collins P, et al. Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355(2): 125–137.
  130. Kawai M, Mödder U, Khosla S, et al. Emerging therapeutic opportunities for skeletal restoration. Nature Reviews Drug Discovery. 2011; 10(2): 141–156.
  131. Pinkerton JV, Harvey JA, Lindsay R, et al. SMART-5 Investigators. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014; 99(2): E189–E198.
  132. Sewerynek E, Hirnle L, Konstantynowicz J, et al. Miejsce wapnia w terapii i suplementacji: od urodzenia do starości. Terapia. 2018; 26: 70–77.
  133. Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012; 367(1): 40–49.
  134. Pludowski P, Takacs I, Boyanov M, et al. Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement. Nutrients. 2022; 14(7).
  135. Kupisz-Urbańska M, Łukaszkiewicz J, Marcinowska-Suchowierska E. Vitamin D in elderly. In: Özdemir Ö. ed. Vitamin D. Intech Open,, London 2021: 131–156.
  136. Marcinowska-Suchowierska E. Leczenie cholekalcyferolem niedoborów witaminy D u osób dorosłych. Terapia. 2019; 12: 48–54.
  137. Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, et al. Vitamin D Toxicity-A Clinical Perspective. Front Endocrinol (Lausanne). 2018; 9: 550.
  138. Coleman R, Hadji P, Body JJ, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014; 25 Suppl 3(12): iii124–iii137.
  139. Eisen A, Somerfield MR, Accordino MK, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol. 2022; 40(7): 787–800.
  140. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005; 23(16_suppl): 4514–4514.
  141. Gnant M, Hadji P. Prevention of bone metastases and management of bone health in early breast cancer. Breast Cancer Res. 2010; 12(6): 216.
  142. Coleman RE, Marshall H, Cameron D, et al. AZURE Investigators. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011; 365(15): 1396–1405.
  143. van Staa TP, Geusens P, Bijlsma JWJ, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54(10): 3104–3112.
  144. Hofbauer LC, Hamann C, Ebeling PR. Approach to the patient with secondary osteoporosis. Eur J Endocrinol. 2010; 162(6): 1009–1020.
  145. Lim MJ, Kang KY. A Contemporary View of the Diagnosis of Osteoporosis in Patients With Axial Spondyloarthritis. Front Med (Lausanne). 2020; 7: 569449.
  146. Kobza AO, Herman D, Papaioannou A, et al. Understanding and Managing Corticosteroid-Induced Osteoporosis. Open Access Rheumatol. 2021; 13: 177–190.
  147. Głuszko P. Effects of biologic antirheumatic treatments on bone metabolism in rheumatoid arthritis and ankylosing spondylitis. Endokrynol Pol. 2009; 60(2): 115–121.
  148. Hu Q, Zhong X, Tian H, et al. The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data. Front Immunol. 2021; 12: 799575.
  149. Sambataro G, Sambataro D, Polosa R. Emerging potential for bisphosphonates in the treatment of axial spondyloarthritis. Ther Adv Chronic Dis. 2017; 8(6-7): 97–99.
  150. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79(6): 685–699.
  151. Leszczyński P, Korkosz M, Pawlak-Bus K, et al. Diagnostyka i leczenie osteoporozy — zalecenia Polskiego Towarzystwa Reumatologicznego 2015. Forum Reumatologiczne. 2015; 1: 12–24.
  152. Lekamwasam S, Adachi JD, Agnusdei D, et al. Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012; 23(9): 2257–2276.
  153. Florez H, Hernández-Rodríguez J, Muxi A, et al. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology (Oxford). 2020; 59(7): 1574–1580.
  154. Pereira RMR, Perez MO, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020). Arch Osteoporos. 2021; 16(1): 49.
  155. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken). 2017; 69(8): 1095–1110.
  156. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999; 42(11): 2309–2318, doi: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K.
  157. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998; 339(5): 292–299.
  158. Zhang C, Song C. Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives. Front Pharmacol. 2020; 11: 607017.
  159. Starup-Linde J, Frost M, Vestergaard P, et al. Epidemiology of Fractures in Diabetes. Calcif Tissue Int. 2017; 100(2): 109–121.
  160. Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166(5): 495–505.
  161. Schacter GI, Leslie WD. Diabetes and Osteoporosis: Part II, Clinical Management. Endocrinol Metab Clin North Am. 2021; 50(2): 287–297.
  162. Gonnelli S, Caffarelli C, Giordano N, et al. The prevention of fragility fractures in diabetic patients. Aging Clin Exp Res. 2015; 27(2): 115–124.
  163. Kurra S, Fink DA, Siris ES. Osteoporosis-associated fracture and diabetes. Endocrinol Metab Clin North Am. 2014; 43(1): 233–243.
  164. Dhaliwal R, Hans D, Hattersley G, et al. Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study. JBMR Plus. 2020; 4(4): e10346.
  165. Mazziotti G, Frara S, Giustina A. Pituitary Diseases and Bone. Endocr Rev. 2018; 39(4): 440–488.
  166. Dixit M, Poudel SB, Yakar S. Effects of GH/IGF axis on bone and cartilage. Mol Cell Endocrinol. 2021; 519: 111052.
  167. Díez JJ, Sangiao-Alvarellos S, Cordido F. Treatment with growth hormone for adults with growth hormone deficiency syndrome: benefits and risks. Int J Mol Sci. 2018; 19: 893.
  168. di Filippo L, Frara S, Doga M, et al. Hyperprolactinemia and bone. Pituitary. 2020; 23(3): 314–321.
  169. Maffezzoni F, Formenti AM. Acromegaly and bone. Minerva Endocrinol. 2018; 43(2): 168–182.
  170. Giustina A. Acromegaly and Vertebral Fractures: Facts and Questions. Trends Endocrinol Metab. 2020; 31(4): 274–275.
  171. Kim SM, Ryu V, Miyashita S, et al. Thyrotropin, Hyperthyroidism, and Bone Mass. J Clin Endocrinol Metab. 2021; 106(12): e4809–e4821.
  172. Ko YJ, Kim JiY, Lee J, et al. Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. J Prev Med Public Health. 2014; 47(1): 36–46.
  173. Ku EuJ, Yoo WS, Lee EK, et al. Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2021; 106(12): 3655–3667.
  174. Zanocco KA, Yeh MW. Primary Hyperparathyroidism: Effects on Bone Health. Endocrinol Metab Clin North Am. 2017; 46(1): 87–104.
  175. Walker MD, Silverberg SJ, Liu M, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2010; 95(5): 2172–2179.
  176. Silva BC, Bilezikian JP, Silva BC, et al. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018; 32(5): 593–607.
  177. National Institute for Health and Care Excellence. Hyperparathyroidism (primary): diagnosis, assessment and initial management. National Institute for Health and Care Excellence, London 2019.
  178. Sakane EN, Vieira MC, Lazaretti-Castro M, et al. Predictors of Poor Bone Microarchitecture Assessed by Trabecular Bone Score in Postsurgical Hypoparathyroidism. J Clin Endocrinol Metab. 2019; 104(12): 5795–5803.
  179. Cipriani C, Minisola S, Bilezikian JP, et al. Vertebral Fracture Assessment in Postmenopausal Women With Postsurgical Hypoparathyroidism. J Clin Endocrinol Metab. 2021; 106(5): 1303–1311.
  180. Chiodini I, Vainicher CE, Morelli V, et al. Mechanisms in endocrinology: Endogenous subclinical hypercortisolism and bone: a clinical review. Eur J Endocrinol. 2016; 175(6): R265–R282.
  181. Pugliese F, Salcuni AS, Battista C, et al. Prevalence of less severe hypercortisolism in fractured patients admitted in an outpatient clinic for metabolic bone diseases. Endocrine. 2021; 73(1): 203–208.
  182. Guo W, Li F, Zhu C, et al. Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing's disease. J Int Med Res. 2018; 46(1): 492–503.
  183. Hardy RS, Zhou H, Seibel MJ, et al. Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy. Endocr Rev. 2018; 39(5): 519–548.
  184. Sakka SD, Cheung MS. Management of primary and secondary osteoporosis in children. Ther Adv Musculoskelet Dis. 2020; 12: 1759720X20969262.
  185. Bertelli E, DI Frenna M, Cappa M, et al. Hypogonadism in male and female: which is the best treatment? Minerva Pediatr (Torino). 2021; 73(6): 572–587.
  186. Delgado-Ruiz R, Swanson P, Romanos G. Systematic Review of the Long-Term Effects of Transgender Hormone Therapy on Bone Markers and Bone Mineral Density and Their Potential Effects in Implant Therapy. J Clin Med. 2019; 8(6).
  187. Verroken C, Collet S, Lapauw B, et al. Osteoporosis and Bone Health in Transgender Individuals. Calcif Tissue Int. 2022; 110(5): 615–623.
  188. Neto R, Pereira L, Magalhães J, et al. Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4. Clin Kidney J. 2021; 14(11): 2401–2408.
  189. Haarhaus M, Evenepoel P. European Renal Osteodystrophy (EUROD) workgroup, Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA). Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int. 2021; 100(3): 546–558.
  190. Yamamoto J, Nakazawa D, Nishio S, et al. Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study. Ther Apher Dial. 2020; 24(2): 146–153.
  191. Sato M, Inaba M, Yamada S, et al. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab. 2021; 39(6): 1082–1090.
  192. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017; 92(1): 26–36.
  193. Fusaro M, Re Sartò GV, Gallieni M, et al. Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism. Nutrients. 2022; 14(9).
  194. Smout D, Jørgensen HS, Cavalier E, et al. Clinical utility of bone turnover markers in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2022; 31(4): 332–338.
  195. Runesson B, Trevisan M, Iseri K, et al. Fractures and their sequelae in non-dialysis-dependent chronic kidney disease: the Stockholm CREAtinine Measurement project. Nephrol Dial Transplant. 2020; 35(11): 1908–1915.
  196. Hampson G, Elder GJ, Cohen-Solal M, et al. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine. 2021; 73(3): 509–529.
  197. Walicka M, Franek E, Marcinowska-Suchowierska E. Operacja bariatryczna — i co dalej? Trendy w Endokrynologii. 2015; 3: 11–16.
  198. Xu X, Jia X, Mo L, et al. Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis. Bone Res. 2017; 5: 17046.
  199. Seely KD, Kotelko CA, Douglas H, et al. The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis. Int J Mol Sci. 2021; 22(17).
  200. Qian Y, Wang L, Yu L, et al. Pregnancy- and lactation-associated osteoporosis with vertebral fractures: a systematic review. BMC Musculoskelet Disord. 2021; 22(1): 926.
  201. Li LJ, Zhang J, Gao P, et al. Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation-associated osteoporosis. Clin Rheumatol. 2018; 37(11): 3141–3150.
  202. Lee S, Hong N, Kim KJ, et al. Bone Density After Teriparatide Discontinuation With or Without Antiresorptive Therapy in Pregnancy- and Lactation-Associated Osteoporosis. Calcif Tissue Int. 2021; 109(5): 544–553.